{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T13:30:33Z","timestamp":1773063033590,"version":"3.50.1"},"reference-count":22,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T00:00:00Z","timestamp":1766448000000},"content-version":"am","delay-in-days":325,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.clgc.2024.102283","type":"journal-article","created":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T03:31:46Z","timestamp":1733196706000},"page":"102283","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["A French Multicenter Real-Life Study on the Biological and Clinical Parameters Associated With Response to Immune Checkpoint Inhibitors (ICIs) in Second-Line Treatment of Advanced Urothelial Carcinoma: Impact of Antibiotics Administration at the Time of ICIs Initiation"],"prefix":"10.1016","volume":"23","author":[{"given":"Pierre","family":"Grassi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9828-6224","authenticated-orcid":false,"given":"Werner","family":"Hilgers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Romain","family":"Boissier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9267-1770","authenticated-orcid":false,"given":"Alexandre","family":"Bertucci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3901-1985","authenticated-orcid":false,"given":"Damien","family":"Bruyat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florence","family":"Duffaud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Faustine","family":"Enoch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Rochigneux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9500-8598","authenticated-orcid":false,"given":"Julien","family":"Mancini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9727-5710","authenticated-orcid":false,"given":"Jean-Laurent","family":"Deville","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.clgc.2024.102283_bib0001","first-page":"209","article-title":"Global Cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"10.1016\/j.clgc.2024.102283_bib0002","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.juro.2008.03.024","article-title":"Radical cystectomy for carcinoma of the bladder: 2,720 consecutive cases 5 years later","volume":"180","author":"Ghoneim","year":"2008","journal-title":"J Urol"},{"issue":"5","key":"10.1016\/j.clgc.2024.102283_bib0003","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s00345-006-0117-8","article-title":"Staged based directed surveillance of invasive bladder cancer following radical cystectomy: valuable and effective?","volume":"24","author":"Donat","year":"2006","journal-title":"World J Urol"},{"issue":"13","key":"10.1016\/j.clgc.2024.102283_bib0004","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","article-title":"Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma","volume":"383","author":"Powles","year":"2020","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.clgc.2024.102283_bib0005","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1093\/annonc\/mdz127","article-title":"Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up","volume":"30","author":"Fradet","year":"2019","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.clgc.2024.102283_bib0006","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.annonc.2022.11.012","article-title":"Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up5","volume":"34","author":"Balar","year":"2023","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.clgc.2024.102283_bib0007","doi-asserted-by":"crossref","first-page":"3173","DOI":"10.1200\/JCO.1999.17.10.3173","article-title":"Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy","volume":"17","author":"Bajorin","year":"1999","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.clgc.2024.102283_bib0008","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1200\/JCO.2009.25.4599","article-title":"Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens","volume":"28","author":"Bellmunt","year":"2010","journal-title":"J Clin Oncol"},{"issue":"16","key":"10.1016\/j.clgc.2024.102283_bib0009","doi-asserted-by":"crossref","first-page":"20468","DOI":"10.18632\/aging.203429","article-title":"The efficacy and safety of PD-1\/PD-L1 immune checkpoint inhibitors in treating advanced urothelial cancer: a meta-analysis of clinical trials","volume":"13","author":"Li","year":"2021","journal-title":"Aging"},{"issue":"6371","key":"10.1016\/j.clgc.2024.102283_bib0010","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1126\/science.aan4236","article-title":"Gut microbiome modulates response to anti\u2013PD-1 immunotherapy in melanoma patients","volume":"359","author":"Gopalakrishnan","year":"2018","journal-title":"Science"},{"issue":"6371","key":"10.1016\/j.clgc.2024.102283_bib0011","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1126\/science.aan3706","article-title":"Gut microbiome influences efficacy of PD-1\u2013based immunotherapy against epithelial tumors","volume":"359","author":"Routy","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.clgc.2024.102283_bib0012","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2020.572912","article-title":"Antibiotics as major disruptors of gut microbiota","volume":"10","author":"Ramirez","year":"2020","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.clgc.2024.102283_bib0013","article-title":"The impact of antibiotic use on clinical features and survival outcomes of cancer patients treated with immune checkpoint inhibitors","volume":"13","author":"Zhou","year":"2022","journal-title":"Front Immunol"},{"issue":"12","key":"10.1016\/j.clgc.2024.102283_bib0014","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.21037\/tlcr-23-597","article-title":"Antibiotic treatment and survival in non-small cell lung cancer patients receiving immunotherapy: a systematic review and meta-analysis","volume":"12","author":"Abdelhamid","year":"2023","journal-title":"Transl Lung Cancer Res"},{"issue":"4","key":"10.1016\/j.clgc.2024.102283_bib0015","first-page":"540","article-title":"Antibiotics impair immunotherapy for urothelial cancer","volume":"78","author":"Derosa","year":"2020","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.clgc.2024.102283_bib0016","doi-asserted-by":"crossref","DOI":"10.1177\/15330338211033498","article-title":"How to choose a survival period? The impact of antibiotic use on OS or PFS in NSCLC patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis","volume":"20","author":"Chen","year":"2021","journal-title":"Technol Cancer Res Treat"},{"issue":"4","key":"10.1016\/j.clgc.2024.102283_bib0017","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.eururo.2020.06.061","article-title":"Concomitant antibiotic use and survival in urothelial carcinoma treated with Atezolizumab","volume":"78","author":"Hopkins","year":"2020","journal-title":"Eur Urol"},{"issue":"12","key":"10.1016\/j.clgc.2024.102283_bib0018","first-page":"834.e21","article-title":"Antibiotic use and survival of patients receiving pembrolizumab for chemotherapy-resistant metastatic urothelial carcinoma","volume":"39","author":"Ishiyama","year":"2021","journal-title":"Urol Oncol Semin Orig Investig"},{"issue":"3","key":"10.1016\/j.clgc.2024.102283_bib0019","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s00262-019-02453-2","article-title":"The effect of antibiotics on clinical outcomes in immune-checkpoint blockade: a systematic review and meta-analysis of observational studies","volume":"69","author":"Wilson","year":"2020","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.clgc.2024.102283_bib0020","unstructured":"Qiu H, Ma QG, Chen XT, et al. Different classes of antibiotics exhibit disparate negative impacts on the therapeutic efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer patients."},{"issue":"4","key":"10.1016\/j.clgc.2024.102283_bib0021","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.3390\/cancers15041066","article-title":"Prognostic value of the Lung Immune prognosis index score for patients treated with Immune checkpoint inhibitors for advanced or metastatic urinary tract carcinoma","volume":"15","author":"Parent","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.clgc.2024.102283_bib0022","doi-asserted-by":"crossref","first-page":"S1340","DOI":"10.1016\/j.annonc.2023.10.106","article-title":"LBA6 EV-302\/KEYNOTE-A39: open-label, randomized phase III study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (Chemo) in previously untreated locally advanced metastatic urothelial carcinoma (la\/mUC)","volume":"34","author":"Powles","year":"2023","journal-title":"Ann Oncol"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767324002532?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767324002532?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T15:20:51Z","timestamp":1753111251000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767324002532"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S1558767324002532"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2024.102283","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A French Multicenter Real-Life Study on the Biological and Clinical Parameters Associated With Response to Immune Checkpoint Inhibitors (ICIs) in Second-Line Treatment of Advanced Urothelial Carcinoma: Impact of Antibiotics Administration at the Time of ICIs Initiation","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2024.102283","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102283"}}